Press Releases

Shanghai, China, November 7, 2025 – WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced the signing of a Memorandum of Understanding (MOU) with Standard Chartered Bank (China) Limited (“Standard Chartered China”). The two parties will establish a comprehensive strategic partnership. Leveraging Standard Chartered China’s global financial network, WuXi XDC will accelerate its global business expansion, strategic planning both domestically and internationally, and the development of the bioconjugate ecosystem.

Under the MOU, Standard Chartered China will support WuXi XDC’s investment and financing activities in global markets and the construction of overseas projects. It will provide comprehensive financial services including cross-border settlement and foreign exchange risk management to ensure secure and efficient cross-border financial transactions. The collaboration will also enhance WuXi XDC’s overall financial flexibility through services such as cross-border cash pooling, bank-enterprise direct connectivity, and cash management. Furthermore, utilizing tailored supply chain finance solutions from Standard Chartered China, the two parties will explore sustainable finance models to boost the R&D and manufacturing of bioconjugate drugs.

Mr. Michael Xi, CFO of WuXi XDC, stated, “This strategic partnership with Standard Chartered China will provide robust financial support for our global expansion, cross-border trade, and domestic and international strategic planning. It will foster innovation and development in sustainable finance and digital finance areas, further enabling WuXi XDC to empower more customers with high-quality CRDMO services for bioconjugate drugs.”

As a leading global CRDMO for bioconjugate drugs, WuXi XDC provides comprehensive, end-to-end CRDMO services to worldwide pharmaceutical and biotech companies. It integrates the entire process from concept to commercialization, accelerating ADCs/XDCs R&D, reducing costs, and benefiting patients. As of June 30, 2025, we have supported our customers in submitting nearly 100 IND applications cumulatively. 13 out of the top 20 global pharmaceutical companies have partnered with us in various stages of projects. Our total number of projects ranks first in the world. By revenue, WuXi XDC currently holds over 22% market share globally, maintaining its leadership in the bioconjugate drug CRDMO sector.

About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from preclinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com

WuXi XDC Contacts

Investor：wuxixdc.ir@wuxibiologics.com

Media：wuxixdc_pr@wuxibiologics.com

BD：wuxixdc_info@wuxibiologics.com